Other Species / Isoforms
  CDC37 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
Y4-p
____MVDysVWDHIE
Upstream
Downstream
1 0
Effects on Modified Protein
  • molecular association, regulation
Kinase, in vitro:
  • Yes (human)
Putative in vivo kinases:
  • Yes (human)
Treatment
  • bpV
  • dasatinib
  • imatinib
  • PP1
  • PP2
  • siRNA
  • SKI-606
CDC37 (human) ____MVDysVWDHIE Y4-p
CDC37 (mouse) ____MVDYSVWDHIE Y4
CDC37 (rat) ____MVDYSVWDHIE Y4
S5-p
___MVDysVWDHIEV
0 3
CDC37 (human) ___MVDysVWDHIEV S5-p
CDC37 (mouse) ___MVDYSVWDHIEV S5
CDC37 (rat) ___MVDYSVWDHIEV S5
S13-p
VWDHIEVsDDEDETH
Upstream
Downstream
13 29
CDC37 (human)
S13-p
CDC37 (mouse)
S13-p
CDC37 (rat)
S13-p
Effects on Modified Protein
  • molecular association, regulation
Kinase, in vitro:
  • CK2A1 (human)
Phosphatases, in vitro:
  • PPP5C (human)
Putative in vivo kinases:
  • CK2A2 (human)
Treatment
  • anisomycin
  • dasatinib
  • IGF-1
  • imatinib
  • OSU-03012
  • serum
  • sildenafil
  • silmitasertib
  • tanespimycin
  • TBB
  • UV
CDC37 (human) VWDHIEVsDDEDETH S13-p
CDC37 (mouse) VWDHIEVsDDEDETH S13-p
CDC37 (rat) VWDHIEVsDDEDETH S13-p
K45-ac
ERMEQFQkEKEELDR
Upstream
0 1
Treatment
  • MS275
CDC37 (human) ERMEQFQkEKEELDR K45-ac
CDC37 (mouse) ERMEQFQKEKEELDR K45
CDC37 (rat) ERMEQFQKEKEELDR K45
K60-ac
GCRECKRkVAECQRk
0 2
CDC37 (human) GCRECKRkVAECQRk K60-ac
CDC37 (mouse) GCRECKRKVAECQRK K60
CDC37 (rat) GCRECKRKVAECQRK K60
K67-ub
kVAECQRkLkELEVA
0 1
CDC37 (human) kVAECQRkLkELEVA K67-ub
CDC37 (mouse) KVAECQRKLkELEVA K67
CDC37 (rat) KVAECQRKLKELEVA K67
K69-ac
AECQRkLkELEVAEG
0 1
CDC37 (human) AECQRkLkELEVAEG K69-ac
CDC37 (mouse) AECQRKLKELEVAES K69
CDC37 (rat) AECQRKLKELEVAEG K69
K69-ub
AECQRkLkELEVAEG
0 9
CDC37 (human) AECQRkLkELEVAEG K69-ub
CDC37 (mouse) AECQRKLkELEVAES K69-ub
CDC37 (rat) AECQRKLKELEVAEG K69
K78-ac
LEVAEGGkAELERLQ
0 17
CDC37 (human) LEVAEGGkAELERLQ K78-ac
CDC37 (mouse) EVAESDGQVELERLR Q79
CDC37 (rat) EVAEGGGQVELERLR Q79
K93-ub
AEAQQLRkEERsWEQ
0 1
CDC37 (human) AEAQQLRkEERsWEQ K93-ub
CDC37 (mouse) AEAQQLRKEERSWEQ K94
CDC37 (rat) AEAQQLRKEERSWEQ K94
S97-p
QLRkEERsWEQkLEE
Upstream
Downstream
1 1
Effects on Modified Protein
  • molecular association, regulation
  • protein stabilization
Kinase, in vitro:
  • PKACA (human)
Putative in vivo kinases:
  • PKACA (human)
Treatment
  • ibuprofen
CDC37 (human) QLRkEERsWEQkLEE S97-p
CDC37 (mouse) QLRKEERSWEQKLED S98
CDC37 (rat) QLRKEERSWEQKLED S98
K101-ub
EERsWEQkLEEMRKK
0 3
CDC37 (human) EERsWEQkLEEMRKK K101-ub
CDC37 (mouse) EERSWEQKLEDMRKK K102
CDC37 (rat) EERSWEQKLEDMRKK K102
K110-ub
EEMRKKEksMPWNVD
0 4
CDC37 (human) EEMRKKEksMPWNVD K110-ub
CDC37 (mouse) EDMRKKEKNMPWNVD K111
CDC37 (rat) EDMRKKEKNMPWNVD K111
S111-p
EMRKKEksMPWNVDt
0 1
CDC37 (human) EMRKKEksMPWNVDt S111-p
CDC37 (mouse) DMRKKEKNMPWNVDt N112
CDC37 (rat) DMRKKEKNMPWNVDT N112
T118-p
sMPWNVDtLskDGFS
0 3
CDC37 (human) sMPWNVDtLskDGFS T118-p
CDC37 (mouse) NMPWNVDtLsKDGFS T119-p
CDC37 (rat) NMPWNVDTLSKDGFS T119
S120-p
PWNVDtLskDGFSks
0 9
CDC37 (human) PWNVDtLskDGFSks S120-p
CDC37 (mouse) PWNVDtLsKDGFSKS S121-p
CDC37 (rat) PWNVDTLSKDGFSKS S121
K121-ub
WNVDtLskDGFSksM
0 4
CDC37 (human) WNVDtLskDGFSksM K121-ub
CDC37 (mouse) WNVDtLsKDGFSKSM K122
CDC37 (rat) WNVDTLSKDGFSKSM K122
K126-ub
LskDGFSksMVNtkP
0 1
CDC37 (human) LskDGFSksMVNtkP K126-ub
CDC37 (mouse) LsKDGFSKSMVNTkP K127
CDC37 (rat) LSKDGFSKSMVNTKP K127
S127-p
skDGFSksMVNtkPE
1 2
CDC37 (human) skDGFSksMVNtkPE S127-p
CDC37 (mouse) sKDGFSKSMVNTkPE S128
CDC37 (rat) SKDGFSKSMVNTKPE S128
T131-p
FSksMVNtkPEktEE
1 1
CDC37 (human) FSksMVNtkPEktEE T131-p
CDC37 (mouse) FSKSMVNTkPEKAEE T132
CDC37 (rat) FSKSMVNTKPEKAEE T132
K132
SksMVNtKPEktEED
0 1
CDC37 (human) SksMVNtKPEktEED K132
CDC37 (mouse) SKSMVNTkPEKAEED K133-ub
CDC37 (rat) SKSMVNTKPEKAEED K133
K132-sm
SksMVNtkPEktEED
0 2
CDC37 (human) SksMVNtkPEktEED K132-sm
CDC37 (mouse) SKSMVNTKPEKAEED K133
CDC37 (rat) SKSMVNTKPEKAEED K133
K135-ub
MVNtkPEktEEDsEE
0 1
CDC37 (human) MVNtkPEktEEDsEE K135-ub
CDC37 (mouse) MVNTkPEKAEEDsEE K136
CDC37 (rat) MVNTKPEKAEEDSEE K136
T136-p
VNtkPEktEEDsEEV
0 1
CDC37 (human) VNtkPEktEEDsEEV T136-p
CDC37 (mouse) VNTkPEKAEEDsEEA A137
CDC37 (rat) VNTKPEKAEEDSEEA A137
S140-p
PEktEEDsEEVREQK
0 3
CDC37 (human) PEktEEDsEEVREQK S140-p
CDC37 (mouse) PEKAEEDsEEAREQK S141-p
CDC37 (rat) PEKAEEDSEEAREQK S141
K154-ac
KHKTFVEkYEkQIKH
0 7
CDC37 (human) KHKTFVEkYEkQIKH K154-ac
CDC37 (mouse) KHKTFVEKYEKQIKH K155
CDC37 (rat) KHKTFVEkYEkQIkH K155-ac
K157-ac
TFVEkYEkQIKHFGM
0 2
CDC37 (human) TFVEkYEkQIKHFGM K157-ac
CDC37 (mouse) TFVEKYEKQIKHFGM K158
CDC37 (rat) TFVEkYEkQIkHFGM K158-ac
K160
EkYEkQIKHFGMLRR
0 1
CDC37 (human) EkYEkQIKHFGMLRR K160
CDC37 (mouse) EKYEKQIKHFGMLHR K161
CDC37 (rat) EkYEkQIkHFGMLHR K161-ac
K240-ac
CFRQFFTkIKTADrQ
0 1
CDC37 (human) CFRQFFTkIKTADrQ K240-ac
CDC37 (mouse) CFRQFFTKIKTADHQ K241
CDC37 (rat) CFRQFFTKIKTADQQ K241
R246-m1
TkIKTADrQYMEGFN
0 1
CDC37 (human) TkIKTADrQYMEGFN R246-m1
CDC37 (mouse) TKIKTADHQYMEGFk H247
CDC37 (rat) TKIKTADQQYMEGFK Q247
N253
rQYMEGFNDELEAFk
0 1
CDC37 (human) rQYMEGFNDELEAFk N253
CDC37 (mouse) HQYMEGFkYELEAFK K254-ac
CDC37 (rat) QQYMEGFKYELEAFK K254
K260-ub
NDELEAFkERVRGRA
0 2
CDC37 (human) NDELEAFkERVRGRA K260-ub
CDC37 (mouse) kYELEAFKERVRGRA K261
CDC37 (rat) KYELEAFKERVRGRA K261
Y278-p
IEKAMKEyEEEERKK
0 89
CDC37 (human) IEKAMKEyEEEERKK Y278-p
CDC37 (mouse) IEKAMKEyEEEERKK Y279-p
CDC37 (rat) IEKAMKEYEEEERKK Y279
Y298-p
GLDPVEVyEsLPEEL
Upstream
Downstream
1 146
Effects on Modified Protein
  • molecular association, regulation
Kinase, in vitro:
  • Yes (human)
Putative in vivo kinases:
  • Yes (human)
Treatment
  • bpV
  • dasatinib
  • imatinib
  • PP1
  • PP2
  • siRNA
  • SKI-606
CDC37 (human) GLDPVEVyEsLPEEL Y298-p
CDC37 (mouse) GLDPVEVyEsLPEEL Y299-p
CDC37 (rat) GLDPVEVYESLPEEL Y299
S300-p
DPVEVyEsLPEELQk
0 10
CDC37 (human) DPVEVyEsLPEELQk S300-p
CDC37 (mouse) DPVEVyEsLPEELQk S301-p
CDC37 (rat) DPVEVYESLPEELQK S301
K307-ub
sLPEELQkCFDVkDV
0 9
CDC37 (human) sLPEELQkCFDVkDV K307-ub
CDC37 (mouse) sLPEELQkCFDVKDV K308-ub
CDC37 (rat) SLPEELQKCFDVKDV K308
K312-ub
LQkCFDVkDVQMLQD
0 1
CDC37 (human) LQkCFDVkDVQMLQD K312-ub
CDC37 (mouse) LQkCFDVKDVQMLQD K313
CDC37 (rat) LQKCFDVKDVQMLQD K313
S322-p
QMLQDAIskMDPTDA
0 3
CDC37 (human) QMLQDAIskMDPTDA S322-p
CDC37 (mouse) QMLQDAISKMDPTDA S323
CDC37 (rat) QMLQDAISKMDPTDA S323
K323-ub
MLQDAIskMDPTDAk
0 2
CDC37 (human) MLQDAIskMDPTDAk K323-ub
CDC37 (mouse) MLQDAISKMDPTDAk K324
CDC37 (rat) MLQDAISKMDPTDAK K324
K330-ac
kMDPTDAkYHMQRCI
0 2
CDC37 (human) kMDPTDAkYHMQRCI K330-ac
CDC37 (mouse) KMDPTDAKYHMQRCI K331
CDC37 (rat) KMDPTDAKYHMQRCI K331
K330-ub
kMDPTDAkYHMQRCI
0 7
CDC37 (human) kMDPTDAkYHMQRCI K330-ub
CDC37 (mouse) KMDPTDAkYHMQRCI K331-ub
CDC37 (rat) KMDPTDAKYHMQRCI K331
S339-p
HMQRCIDsGLWVPNs
Upstream
Downstream
1 1
Effects on Modified Protein
  • molecular association, regulation
Kinase, in vitro:
  • ULK1 (human)
Putative in vivo kinases:
  • ULK1 (human)
CDC37 (human) HMQRCIDsGLWVPNs S339-p
CDC37 (mouse) HMQRCIDSGLWVPNS S340
CDC37 (rat) HMQRCIDSGLWVPNS S340
S346-p
sGLWVPNskASEAkE
0 1
CDC37 (human) sGLWVPNskASEAkE S346-p
CDC37 (mouse) SGLWVPNSkSGEAkE S347
CDC37 (rat) SGLWVPNSKSGEAKE S347
K347-ub
GLWVPNskASEAkEG
0 23
CDC37 (human) GLWVPNskASEAkEG K347-ub
CDC37 (mouse) GLWVPNSkSGEAkEG K348-ub
CDC37 (rat) GLWVPNSKSGEAKEG K348
K352-ub
NskASEAkEGEEAGP
0 8
CDC37 (human) NskASEAkEGEEAGP K352-ub
CDC37 (mouse) NSkSGEAkEGEEAGP K353-ub
CDC37 (rat) NSKSGEAKEGEEAGP K353
K369-ub
PLLEAVPktGDEkDV
0 1
CDC37 (human) PLLEAVPktGDEkDV K369-ub
CDC37 (mouse) PLLEAVPKAGNEKDV K370
CDC37 (rat) PLLEAVPKAGNEKDI K370
T370-p
LLEAVPktGDEkDVs
0 3
CDC37 (human) LLEAVPktGDEkDVs T370-p
CDC37 (mouse) LLEAVPKAGNEKDVs A371
CDC37 (rat) LLEAVPKAGNEKDIS A371
K374-ub
VPktGDEkDVsV___
0 2
CDC37 (human) VPktGDEkDVsV___ K374-ub
CDC37 (mouse) VPKAGNEKDVsA___ K375
CDC37 (rat) VPKAGNEKDISA___ K375
S377-p
tGDEkDVsV______
Upstream
0 10
Treatment
  • ischemia
  • MLN8054
CDC37 (human) tGDEkDVsV______ S377-p
CDC37 (mouse) AGNEKDVsA______ S378-p
CDC37 (rat) AGNEKDISA______ S378